Cases & Deals

Johnson & Johnson announces $438 million acquisition of Omrix Biopharmaceuticals

Clients Johnson & Johnson

Jones Day acted as tax counsel to Johnson & Johnson in its approximately $438 million acquisition of Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. The acquisition was completed on December 30, 2008.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.